Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies

Alzheimer's and Dementia

Volumn 8, Issue 5, 2012, Pages 407-416

  Henley, David B ^a   Sundell, Karen L ^a   Sethuraman, Gopalan ^a   Siemers, Eric R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

ADNI; Adverse events; Alzheimer's disease; Clinical outcomes; Epidemiology; Risk assessment; Safety monitoring

Indexed keywords

ATORVASTATIN; BAPINEUZUMAB; HYDROXYCHLOROQUINE; PLACEBO; TARENFLURBIL; VITAMIN B GROUP;

AGITATION; ALZHEIMER DISEASE; ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BLURRED VISION; CATARACT; CAUSE OF DEATH; CLINICAL ASSESSMENT; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSPNEA; FALLING; FRACTURE; GAIT DISORDER; GEOGRAPHIC DISTRIBUTION; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; JOINT SWELLING; MORTALITY; NAUSEA; NEUROIMAGING; PARANOIA; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; RHINITIS; RHINOPHARYNGITIS; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SKIN INJURY; SYNCOPE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROIMAGING; PLACEBOS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84866118711     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2011.05.2413     Document Type: Article

References (29)

1. J. Lindsay, D. Laurin, R. Verreault, R. Hébert, B. Helliwell, and G.B. Hill Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging Am J Epidemiol 156 2002 445 453 (Pubitemid 34976983)
2. L.J. Launer, K. Andersen, M.E. Dewey, Letenneur, A. Ott, and L.A. Amaducci Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia Neurology 52 1999 78 84 (Pubitemid 29044403)
3. L.E. Hebert, P.A. Scherr, L.A. Beckett, M.S. Albert, D.M. Pilgrim, and M.J. Chown Age-specific incidence of Alzheimer's disease in a community population JAMA 273 1995 1354 1359
4. L.X. Hy, and D.M. Keller Prevalence of AD among whites: a summary by levels of severity Neurology 55 2000 198 204 (Pubitemid 30604618)
5. L.E. Hebert, P.A. Scherr, J.L. Bienias, D.A. Bennett, and D.A. Evans Alzheimer's disease in the U.S. population: prevalence estimates using the 2000 census Arch Neurol 60 2003 1119 1122 (Pubitemid 36975801)
6. M.P. Heron, D.L. Hoyert, J. Xu, C. Scott, and B. Tejada-Vera Deaths: preliminary data for 2006 Natl Vital Stat Rep 56 2008 1 51 cited November 22, 2010. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-16.pdf
7. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias [Internet]. Available at: http://www.ema.europa.eu/ ema/pages/includes/document/open-document.jsp?webContentId=WC500003562.
8. B. Vellas, S. Andrieu, C. Sampaio, G. Wilcock European Task Force group Disease-modifying trials in Alzheimer's disease: a European task force consensus Lancet Neurol 6 2007 56 62 (Pubitemid 44880273)
9. J.P. Bynum, P.V. Rabins, W. Weller, M. Niefeld, G.F. Anderson, and A.W. Wu The relationship between a dementia diagnosis, chronic illness, Medicare expenditures, and hospital use J Am Geriatr Soc 52 2004 187 194 (Pubitemid 38233479)
10. L.S. Schneider, and M. Sano Current Alzheimer's disease clinical trials: methods and placebo outcomes Alzheimers Dement 5 2009 388 397
11. Council for International Organizations of Medical Sciences (CIOMS) Management of safety information from clinical trials: report of CIOMS Working Group VI 2005 World Health Organization Geneva, Switzerland p. 111
12. ICH E6: Good Clinical practice: Consolidated guideline. [Internet] Directive 75/318/EEC. CPMP/ICH/135/95 1996: Sections 5.16.1-5.16.2. European Commission; 1997; cited November 22, 2010. Available at: http://ec.europa.eu/ health/files/eudralex/vol-10/3cc1aen-en.pdf.
13. Investigational New Drug Application: IND Safety Reports, 21 C.F.R. Sect. 312.32b [Internet]; 2001; cited November 22, 2010. Available at: http://edocket.access.gpo.gov/cfr-2001/aprqtr/21cfr312.32.htm.
14. Investigational New Drug Application: review of ongoing investigations, 21 C.F.R. Section 312.56a [Internet]; 2001; cited November 22, 2010. Available at: http://edocket.access.gpo.gov/cfr-2001/aprqtr/21cfr312.56.htm.
15. Council for International Organizations of Medical Sciences (CIOMS) Management of safety information from clinical trials: report of CIOMS Working Group VI 2005 World Health Organization Geneva, Switzerland p. 67
16. Food and Drug Administration HHS Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans Fed Regist 75 2010 59935 21 CFR Parts 312 and 320. Final rule. Available at: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=2010- register&docid=fr29se10-3.pdf Accessed November 22, 2010
17. Food and Drug Administration, HHS. Guidance for Industry and Investigators: Safety reporting requirements for investigational new drug and bioavailability and bioequivalence studies: draft guidance, 2010. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM227351.pdf. Accessed April 22, 2011.
18. W.A. Van Gool, H.C. Weinstein, P. Scheltens, and G.J. Walstra Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study Lancet 358 2001 455 460 (Pubitemid 32769852)
19. PhRMA Web Synopsis. Protocol A2581078. 01 June 2008 Final. Lipitor/atorvastatin: An 80-week, randomized, multi-center, parallel-group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer's disease [Internet]; 2008; cited November 22, 2010. Available at: http://www.clinicalstudyresults.org/documents/ company-study-4374-0.pdf.
20. H.H. Feldman, R.S. Doody, M. Kivipelto, D.L. Sparks, D.D. Watters, and R.W. Jones Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe Neurology 74 2010 956 964
21. P.S. Aisen, L.S. Schneider, M. Sano, R. Diaz-Arrastia, C.H. van Dyck, and M.F. Weiner High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA 300 2008 1774 1783
22. R.C. Green, L.S. Schneider, D.A. Amato, A.P. Beelen, G. Wilcock, and E.A. Swabb Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA 302 2009 2557 2564
23. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blenow, and M. Raskind A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
24. Alzheimer's Disease Neuroimaging Initiative (ADNI) database; updated January 5, 2010. Available at: www.loni.ucla.edu/ADNI. Accessed January 6, 2010.
25. K. Sundell, D.B. Henley, G. Sethuraman, and E.R. Siemers Safety profile of Alzheimer's disease populations over 18 months using ADNI and controlled clinical trial data Alzheimer Dement 6 Suppl 4 2010 S306
26. Alzheimer's Disease Cooperative Study (ADCS). Regents of California; 2008; cited November 22, 2010. Available at: http://www.ADCS.org.
27. Critical Path Institute [Internet home page]. Critical Path Institute; 2008-2010; cited November 22, 2010. Available at: http://www.c-path.org/about. cfm.
28. US Food and Drug Administration. Critical Path Initiative [Internet]. US Department of Health and Human Services; 2010; cited November 22, 2010. Available at: http://www.fda.gov/ScienceResearch/SpecialTopics/ CriticalPathInitiative/default.htm.
29. Critical Path Institute. C-Path Online Data Repository (CODR). Available at: http://www.c-path.org/CAMDcodr.cfm. Accessed September 20, 2010.